Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The company absolutely crushed analysts' Q3 estimates.

Why Co-Diagnostics Shot Almost 8% Higher Today

The stock price of Co-Diagnostics Inc (NASDAQ: CODX) increased by over 6% pre-market today. This is why it happened.

Co-Diagnostics (CODX) Stock: Why The Price Increased Today

Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q3 2021 Results - Earnings Call Transcript

Co-Diagnostics (NASDAQ:CODX) Inc has announced record third-quarter 2021 revenue of $30.1 million, a 38% year-over-year increase, which the company attributed primarily to sales of its Logix Smart coronavirus (COVID-19) test. Co-Diagnostics (NASDAQ:CODX) also recorded a 67.5% increase in its gross profit for the quarter to $26.8 million, representing 89% of consolidated revenue due to improved product mix as compared to the same period last year.

Co-Diagnostics sees record 3Q revenue of $30.1M on Logix Smart coronavirus test sales

SALT LAKE CITY, Nov. 11, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the third quarter ended September 30, 2021. Solid quarterly results highlighted by record revenue of $30.1 million, and fully diluted EPS of $0.38     Third Quarter 2021 Financial Results: Revenue increased 38.0% as compared to the prior year period to a record $30.1 million, primarily due to sales of the Logix Smart™ COVID-19 Test.

Co-Diagnostics Reports Continued Strength in Third Quarter 2021 Financial Results

Co-Diagnostics (NASDAQ:CODX) Inc has said it will be awarded the 'Innovation Impact Award' at the 2021 BioUtah Life Sciences awards which will be presented on Friday, November 12, 2021, during a virtual ceremony in which pre-recorded videos of the winners will be unveiled.  Co-Diagnostics CEO Dwight Egan will accept the award on behalf of the company.

Co-Diagnostics says it will be awarded the 'Innovation Impact Award' at the 2021 BioUtah Life Sciences awards

CoDiagnostics, Inc. (CODX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate CoDiagnostics, Inc. (CODX) to Report a Decline in Earnings: What to Look Out for

Co-Diagnostics (NASDAQ:CODX) Inc has announced that its Logix Smart SARS-CoV-2 2-Gene multiplex test is now available for sale in the UK after being validated according to the United Kingdom Health Security Agency's (UKHSA) Medical Devices Regulations 2021 under Coronavirus Test Device Approvals (CTDA). The company said the Logix Smart test is available for sale through Client Life Science, Co-Diagnostics (NASDAQ:CODX)' authorized distributor in the UK.

Co-Diagnostics says its Logix Smart COVID-19 test has been approved for sale in the UK

SALT LAKE CITY, Nov. 4, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ SARS-CoV-2 2-Gene multiplex test has been validated according to the United Kingdom Health Security Agency's ("UKHSA") Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 ("CTDA") and is available for sale in the UK under the Regulation. The UKHSA is the agency responsible for planning, preventing, and responding to external health threats, replacing Public Health England earlier this year.

Co-Diagnostics, Inc. Logix Smart™ COVID-19 2-Gene Test Approved for Use in the United Kingdom

Fulgent Genetics

They're already competing in fresh markets now that their COVID test revenue is ebbing.

Got $1,500? These 2 COVID Stocks Are Firing On All Cylinders

SALT LAKE CITY, Oct. 28, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2021 results on Thursday, November 11, 2021, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.

Co-Diagnostics, Inc. Announces Third Quarter 2021 Earnings Release Date And Webcast

Co-Diagnostics Inc., revealed that CoSara Diagnostics Pvt Ltd., its joint venture for manufacturing and sales in India, has received clearance from the Central Drugs Standard Control Organization (CDSCO) in India to manufacture and sell its Saragene Dengue and Chikungunya Multiplex RT-PCR test as an in vitro diagnostic (IVD).

Co-Diagnostics says its CoSara JV wins clearance in India for Saragene Dengue and Chikungunya Multiplex Test

Co-Diagnostics says it CoSara JV wins clearance in India for Saragene Dengue and Chikungunya Multiplex Test

SALT LAKE CITY, Oct. 6, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its Saragene™ Dengue and Chikungunya Multiplex RT-PCR test as an in vitro diagnostic ("IVD"). The CDSCO approval marks the 10th assay manufactured and sold by CoSara to receive clearance from the CDSCO, and follows the recent clearance of standalone dengue and chikungunya assays last month.

Co-Diagnostics JV CoSara Receives Clearance from Indian Regulators for Dengue/Chikungunya Multiplex Test

Develops products to detect infectious diseases in humans and animals Offers Logix Smart coronavirus detection test in US and globally Amassed balance sheet of $72.4 million What Co-Diagnostics does:  Co-Diagnostics Inc is a molecular diagnostics company that develops products to detect infectious diseases in humans and animals. The company also develops tools for liquid-biopsy cancer screening and agricultural uses.

Co-Diagnostics fighting coronavirus (COVID-19) with flagship test, plans at-home PCR-based platform for the masses

Co-Diagnostics, Inc. has said it will be introducing its upcoming at-home and point-of-care PCR device at a press conference at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo being held September 26-30, 20321, in Atlanta, Georgia.

Co-Diagnostics to introduce its upcoming at-home and point-of-care PCR device at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo

SALT LAKE CITY, Sept. 27, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be introducing its upcoming at-home and point-of-care PCR device in a press conference at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, held September 26-30 in Atlanta, GA, as well as hosting a booth to promote its existing suite of diagnostics products and technology applications.

Co-Diagnostics, Inc. to Introduce At Home/Point of Care Device at AACC on Sept 28

Co-Diagnostics Inc. is rebranding its image to better reflect its growing scope, mission, and upcoming expansion into new diagnostics verticals.

Co-Diagnostics announces corporate rebranding after period of transformative growth and expansion

SALT LAKE CITY, Sept. 23, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that following its recent transformative growth, the Company is rebranding its image to better reflect its expanded scope, mission, and upcoming expansion into new diagnostics verticals.

Co-Diagnostics, Inc. Announces Corporate Rebranding Following Period of Transformative Growth and Expansion

SALT LAKE CITY, Sept. 21, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company representatives will be presenting at the 5th Advances in Circulating Tumor Cells (ACTC) conference in Kalamata, Greece, held on September 22-25, 2021.

Co-Diagnostics, Inc. to Present at ACTC Liquid Biopsy Conference in Kalamata, Greece

Co-Diagnostics Inc has announced that its Logix Smart Influenza A/Influenza B/COVID-19 "ABC" Test has been approved for sale in Mexico by the Mexican Department of Epidemiology (InDRE) after the department successfully concluded an independent evaluation of the test's sensitivity and specificity for use as an RT-PCR multiplex test in that market. The InDRE, which is comparable to the US Centers for Disease Control and Prevention (CDC), is required to evaluate any test used to detect coronavirus (COVID-19) before the test may gain clearance to be sold into the Mexican healthcare market, Co-Diagnostics said.

Co-Diagnostics says its Logix Smart ABC Test is authorized for use in Mexico

SALT LAKE CITY, Sept. 21, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ Influenza A/Influenza B/COVID-19 "ABC" Test has been approved for sale in Mexico by the Mexican Department of Epidemiology ("InDRE") after InDRE successfully concluded an independent evaluation of the test's sensitivity and specificity for use as an RT-PCR multiplex test in that market.

Co-Diagnostics, Inc. Logix Smart™ ABC Test Authorized for Use in Mexico

SALT LAKE CITY, Sept. 20, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX) a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Dwight Egan, CEO, Brian Brown, CFO, and Andrew Benson, Head of Investor Relations, will present and host one-on-one meetings with investors at the Sidoti Fall Virtual Investor Conference.

Co-Diagnostics, Inc. to Present at Sidoti Virtual Investor Conference

Co-Diagnostics (NASDAQ:CODX) Inc has announced that CoSara Diagnostics Pvt Ltd, its joint venture for manufacturing and sales in India, has received clearance from the Central Drugs Standard Control Organization (CDSCO) in India to manufacture and sell its Saragene dengue and chikungunya RT-PCR tests as in vitro diagnostics (IVD). The Saragene test kits approved by the CDSCO use the company's patented CoPrimer technology for the qualitative detection of these mosquito-borne viruses.

Co-Diagnostics says its CoSara JV received regulatory clearance in India for Saragene dengue and chikungunya tests

Co-Diagnostics Inc has announced that CoSara Diagnostics Pvt Ltd, its joint venture for manufacturing and sales in India, has received clearance from the Central Drugs Standard Control Organization (CDSCO) in India to manufacture and sell its Saragene dengue and chikungunya RT-PCR tests as in vitro diagnostics (IVD). The Saragene test kits approved by the CDSCO use the company's patented CoPrimer technology for the qualitative detection of these mosquito-borne viruses.

News for Co-Diagnostics Stock (CODX)